Oral Dronabinol-HIV - Trial NCT06034314
Access comprehensive clinical trial information for NCT06034314 through Pure Global AI's free database. This Phase 1 trial is sponsored by Yale University and is currently Not yet recruiting. The study focuses on HIV. Target enrollment is 160 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Yale University
Timeline & Enrollment
Phase 1
Oct 01, 2023
Oct 01, 2027
Primary Outcome
Change in Dronabinol-induced transcriptome profile in blood using single cell (sc)RNA-seq
Summary
The purpose of this study is to define the mechanisms of cannabis on the genome of people
 with HIV who use cannabis. The investigator aims to better understand the effect of
 Dronabinol on immune and inflammatory functions, and whether these changes are HIV-status
 dependent. This research may better inform public health policy regarding cannabis use.
 Depending on the results, additional studies may also build upon this research to develop
 more effective and specific treatments for cannabis use associated disorders.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06034314
Non-Device Trial